Impact of non-regional lymph node metastases accurately revealed on 18 F-PSMA-1007 PET/CT in the clinical management of metastatic hormone-sensitive prostate cancer.

F-PSMA-1007 PET/CT, which should be considered a high-volume feature, especially concomitant with bone metastases. Furthermore, patients with low-volume plus NRLN metastases may be suitable for more intensive treatment, such as early docetaxel chemotherapy.